This report covers several technologies, epigenetic targets, and market outlook. The first part of this report covers necessary background information, mostly pertaining to epigenetic targets, and the reasons they are being investigated. Several companies have kindly disclosed several strategies, methods, and techniques that they use for either target identification or technology development.

In Part I of the report, several targets and their properties are discussed including histone methyltransferases, histone demethylases, and bromodomains. A list of known histone modifications is also present. This includes companies (if applicable), targets being studied, diseases they are associated with, and their clinical developmental status. Part II details specific pharmaceutical/biopharmaceutical companies and their strategies behind their target identifications and validation. These companies include Constellation Pharmaceuticals, Epizyme Inc., and EpiTherapeutics. Part III of the report covers technologies and assays available from the following biotechnology companies: Active Motif (including ChIP technology and a current list of validated antibodies), Cayman Chemical, and Reaction Biology.

Areas covered for Parts I and II include:
• Company backgrounds
• Areas of interest
• Challenges encountered
• Competitive advantages
• Partnerships

Additionally, these sections also include interviews with CEOs, CSOs, and expert scientists of the participating companies.

The last section of the report, Part IV, gives insight into the epigenetics community. Insight Pharma Reports polled a survey which had more than 150 responses. Specific areas highlighted are targets under investigation, market outlook, and how partnerships with external organizations have advanced the industry.

Table Of Contents

Executive Summary

Part I: Epigenetic Background and Target Information

Chapter 1
• What is epigenetics?
• Histone modifications
- Histone methyltransferases
- Arginine methyltransferases (RMT)
- Histone demethylases
- Epigenetic readers

Part II: Targets in the Industry

Chapter 2
• Constellation Pharmaceuticals
• Company background
• Areas of research
- SWI/SNF
- EZH2
- DOT1L
- BET bromodomains
• Challenges encountered
• Competitive advantage
• Partnerships
• Future endeavors
• Interview with Robert Sims
- Company background
- Research objectives
- Benefits and challenges
- Future endeavors

Chapter 3
• EpiTherapeutics
• Company background
• Areas of research
- PLU1
- FBXL10
- GASC1
• Chemistry platform
• Challenges encountered
• Competitive advantage
• Partnerships and future endeavors
• Interview with Martin Bonde
- Company background
- Areas of research
- Chemistry platform
- Challenges encountered
- Competitive advantage
- Partnerships
- Future endeavors

Chapter 4
• Epizyme Inc.
• Company background
• Areas of research
- DOT1L
- EZH2
• Challenges encountered
• Competitive advantage
• Partnerships
• Future endeavors
• Interview with Jesse Smith
- Background
- Areas of research
- Target validation
- Use of biomarkers
- Challenges encountered
- Partnerships
- Future endeavors

Part III: Rising Technologies and Company Strategies

Chapter 5
• Active Motif
• Company background
• Chromatin Immunoprecipitation (ChIP) technology
• Competitive advantage
• Challenges encountered
• Validating antibodies using ChIP, ChIP-chip, and ChIP-Seq
• Partnerships and strategies
• Future endeavors
• Interview with Kyle Hondorp
- Company background
- Immunoprecipitation technology
- Challenges encountered
- Future endeavors
- Partnerships and growth

Chapter 6
• Cayman Chemical
• Company background
• Applications
- Time-resolved fluorescence resonance energy transfer (TR-FRET) assays
- S-adenosyl-L-methionine (SAM)-screener assays
• Challenges encountered
• Partnerships
• Future outlook
• Interview with Dr. Levi Blazer
- Company background
- Partnerships
- Areas of research
- Assays
- Challenges encountered
- Future endeavors

Chapter 7
• Reaction Biology Corporation
• Company background
• Reaction Biology Corporation’s role in epigenetics
• Competitive strategies
• Future outlook
• Interview with Haiching Ma
- Company background
- Areas of research
- Partnerships
- Future expectations

Part IV: Epigenetics in the Community

Chapter 8
• Survey results
• Areas of study
• Market outlook
• Partnerships

References

About Cambridge Healthtech Institute



Tables

Table 1.1 List of known histone modifications in vertebrates
Table 1.2: Targets and their developmental status
Table 5.1: Validated antibodies using ChIP, ChIP-chip, and ChIP-Seq assays



Figures

Figure 1.1: Interest in epigenetic targets over time
Figure 5.1: ChIP-chip validation steps
Figure 5.2: ChIP antibody validation steps
Figure 8.1: Survey participants
Figure 8.2: Popular areas of study
Figure 8.3: Technology of choice
Figure 8.4: Targets of interest
Figure 8.5: Expected diseases to benefit from therapeutic applications
Figure 8.6: Classes expected to receive FDA approval
Figure 8.7: Participants in partnerships
Figure 8.8: Impact of partnerships on research

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Markets for Enzymes in Industrial Applications

Global Markets for Enzymes in Industrial Applications

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Widespread research in the field of industrial enzymes has revealed the influence of enzyme technology in almost every sector of industrial activity, ranging from technical field to food, feed and healthcare ...

Global Markets for Bioengineered Protein Drugs

Global Markets for Bioengineered Protein Drugs

  • $ 6 650
  • Industry report
  • August 2014
  • by BCC Research

This BCC Research report explores the present and future strategies within the bioengineered protein drugs market. It analyzes each market and its applications, regulatory environment, technologies involved, ...

Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

An in-depth analysis of the global nucleic acid aptamer market by technologies, applications and geographic regional markets. This report includes key technologies involved, analyzes the capabilities and ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.